A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy

Inclusion Criteria: * Histologic proof of breast cancer (invasive ductal or lobular carcinoma - not breast sarcoma or lymphoma) * Patients having a clinical diagnosis of locally advanced breast cancer (T3 or T4, or N2 according to TNM classification) including inflammatory breast cancer. * Patients must be able to undergo neoadjuvant chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 sufficient to undergo chemotherapy Exclusion Criteria: * Previously treated cancer other than nonmelanotic skin cancer or carcinoma in situ of the cervix, unless disease-free for 5 years or greater. * Evidence of metastatic disease (found on chest X-ray, liver ultrasound or bone scan). * Previous chemotherapy or hormonal therapy for breast cancer. * Active infection or other significant illnesses which could hamper their ability to tolerate chemotherapy * Significant concurrent medical problems (e.g. uncontrolled diabetes, active cardiac disease, severe chronic obstructive pulmonary disease) making the patient unfit for surgery. * Any condition that could interfere with their ability to provide informed consent such as dementia or severe cognitive impairment. * Pregnant or lactating females (e.g. positive serum B-hCG pregnancy test). * Unable to lie supine for imaging with PET. * Inadequate hematologic, renal and liver function as measured by CBC (WBC \< 4.0 x 109, Hb \< 100 g/L, plt count \< 100 x 109), and abnormal hepatic transaminases (AST, ALT, GGT, …